BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 3.4% - Time to Sell?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report)'s share price dropped 3.4% on Tuesday . The stock traded as low as $7.65 and last traded at $7.66. Approximately 84,786 shares changed hands during trading, a decline of 96% from the average daily volume of 2,174,724 shares. The stock had previously closed at $7.93.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BCRX. Barclays upped their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. Evercore ISI lifted their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday. Royal Bank of Canada restated an "outperform" rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Needham & Company LLC increased their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Monday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $15.17.

BioCryst Pharmaceuticals Trading Down 8.8 %

The company's fifty day simple moving average is $7.60 and its 200 day simple moving average is $7.60. The stock has a market capitalization of $1.50 billion, a P/E ratio of -11.85 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $117.10 million for the quarter, compared to analysts' expectations of $113.99 million. During the same period in the previous year, the firm posted ($0.19) EPS. The firm's revenue for the quarter was up 35.1% compared to the same quarter last year. Equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

Institutional Trading of BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of BCRX. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock worth $57,000 after purchasing an additional 1,322 shares during the last quarter. DRW Securities LLC purchased a new stake in BioCryst Pharmaceuticals during the 2nd quarter valued at $74,000. Xponance Inc. grew its holdings in BioCryst Pharmaceuticals by 13.1% in the 2nd quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 1,505 shares during the last quarter. Quantinno Capital Management LP bought a new stake in BioCryst Pharmaceuticals in the 3rd quarter worth $82,000. Finally, SkyView Investment Advisors LLC increased its position in shares of BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company's stock valued at $99,000 after acquiring an additional 3,000 shares during the period. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.